Phase II FANG™ in Advanced Melanoma

Inclusion Criteria:

1. Histologically confirmed Stages IIIc and IV melanoma.

2. Has been informed of all alternative ≥ second-line therapies that are the current
standard of care. If no conventional frontline therapy indicated or acceptable by
patient, patient may participate after review by sponsor.

3. Clinically (medically) indicated procedure (i.e. biopsy of lesions of recurrent
disease, palliative management via resection, thoracentesis, etc.) to collect viable
tumor in sufficient quantity ("golf ball size" estimated weight ~ 30 grams, pleural
and/or ascites fluid estimated volume ≥ 500mL) for vaccine processing.

4. Recovered to ≤ Grade 1 (excluding alopecia) from all clinically relevant toxicities
related to prior therapies.

5. Patients will be allowed to participate following single prior CNS treatment with
stereotactic radiotherapy whole brain irradiation and stable without steroid
requirement for ≥2 months or following ≥2 prior CNS treatments with stereotactic
radiotherapy whole brain irradiation and stable without steroid requirement for ≥4
months.

6. Patients must be off all "statin" drugs for ≥ 2 weeks prior to initiation of therapy.

7. Age ≥18 years.

8. ECOG performance status (PS) 0-1.

9. Estimated >4 month survival probability.

10. Normal organ and marrow function as defined below:

Absolute granulocyte count ≥1,500/mm3 Absolute lymphocyte count ≥500/mm3 Platelets
≥100,000/mm3 Total bilirubin ≤2 mg/dL AST(SGOT)/ALT(SGPT) ≤2x institutional upper
limit of normal Creatinine <1.5 mg/dL

11. Ability to understand and the willingness to sign a written informed consent document.

12. Negative pregnancy test.

Exclusion Criteria:

1. Surgery involving general anesthesia, chemotherapy, radiotherapy, steroid therapy, or
immunotherapy within 4 weeks prior to entering the study. Collection of lumenal tissue
must be avoided.

2. Patient must not have received any other investigational agents within 30 days prior
to study entry.

3. Patients with known active or symptomatic brain metastases.

4. Patients with compromised pulmonary disease.

5. Short term (<30 days) concurrent systemic steroids ≤ 0.25 mg/kg prednisone per day
(maximum 7.5 mg/day) and bronchodilators (inhaled steroids) are permitted; other
steroid regimens and/or immunosuppressives are excluded. Patients requiring steroids
following previous CNS radiation for metastatic disease are excluded.

6. Prior splenectomy.

7. Prior malignancy (excluding nonmelanoma carcinomas of the skin) unless in remission
for 2 years.

8. Kaposi's Sarcoma.

9. Uncontrolled intercurrent illness including, but not limited to ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements.

10. Patients who are pregnant or nursing.

11. Patients with known HIV.

12. Patients with chronic Hepatitis B and C infection.

13. Patients with uncontrolled autoimmune diseases.